GLEN R HANSON

GLEN R HANSON portrait
  • Senior Advisor, NIH, College Of Pharmacy, University of Utah
  • Director Utah Addiction Center, Office Of Sr Vp Health Sci, University of Utah
  • Professor, School Of Dentistry, University of Utah
  • Professor, Pharmacology And Toxicology, University of Utah

Publications

Publications

Search my publications on PubMed or USpace.

  • Alburges, M.E., Hoonakker, A.J., Horner, K.A., Fleckenstein, A.E., and Hanson, G.R.: Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: A comparison with cocaine treatment.J Neurochem. In press (2011). In press, 02/2011.
  • Frankel, P.S., Hoonakker, A.J., Alburges, M.E., McDougall, J., Fleckenstein, A.E., and Hanson, G.R.: Response of Basal Ganglia Neurotensin System to Methamphetamine Self-Administration. J. Pharmacol. Exp. Therapeutics. 336 (2011) 1-7. Published, 01/2011.
  • Chu, P., Hadlock, G., Vieira-Brock, P., Stout, K., Hanson, G.R., and Fleckenstein, A.E.: Methamphetamine Alters Vesicular Monoamine Transporter-2 Function and Potassium-Stimulated Dopamine Release. J Neurochem. 115 (2010) 325-332. Published, 12/2010.
  • Hadlock, G., Chu, P., Walters, E., Hanson, G.R., and Fleckenstein, A.E.: Methamphetamine-Induced Dopamine Transporter Complex Formation and Dopaminergic Deficits: The Role of D2 Receptor Activation. J. Pharmacol. Exp. Ther. 335 (2010) 207-212. Published, 12/2010.
  • Birdsall, E. Hanson, J.E., Crosby, M., Ellis, J., Rowley, S. Sawada, N., West, J., Hanson, G.R., and Fleckenstein, A.E.: Ephedrine Decreases Vesicular Monoamine Transporter-2 Function. Synapse. In press, 12/2010.
  • McFadden, L.M., Hoonakker, A.J., Vieira-Brock, P.L., Stout, K.A., Sawada, N.M., Ellis, J.D., Allen, S.C., Walters, E.T., Nielsen, S.m., Gibb, J.W., Alburges, M.E., Wilkins, D.,G., Hanson, G.R., and Fleckenstein, A.E., Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration. Synapse. In press, 12/2010.
  • Hadlock, G.C., Baucum, A.J. 2nd, King, J.L., Horner, K.A., Cook, G.A., Gibb, J.W., Wilkins, D.G., Hanson, G.R., and Fleckenstein, A.E.: Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. J. Pharmacol. Exp. Ther. 329 (2009) 169-74. Published, 10/2009.
  • Farnsworth, S.J., Volz, T.J., Hanson, G.R., and Fleckenstein, A.E..: Cocaine alters vesicular dopamine sequestration and Potassium-stimulated dopamine release: The role of D2 receptor activation. J. Pharmacol. Exp. Ther. 328 (2009) 1-6. Published, 07/2009.
  • Hanson, J.E., Birdsall, E., Seferian, K., Crosby, M., Keefe, Dristen, Gibb, J., Hanson, G.R., and Fleckenstein, A.E.: Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment. Eur. J. Pharmacol. 607 (2009) 68-73. Published, 07/2009.
  • Fleckenstein, A.E., Volz, T.J. and Hanson, G.R.: Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 56 (2009) 133-138. Published, 06/2009.
  • Volz, T.J., Farnsworth, S.J, Hanson, G.R, and Fleckenstein, A.E.: Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles. J Neurosci Methods. 177 (2009) 177-182. Published, 04/2009.
  • Alburges, M.E., Frankel, P.S., Hoonakker, A.J., Hanson, G.R.: Responses of limbic and extrapyramidal substance P systems to nicotine treatment. Psychopharmacology (Berl) 201 (2009) 517-527. Published, 04/2009.
  • Volz, T.J., Farnsworth, S.J., Rowley, S.D., Hanson, G.R., and Fleckenstein: Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse 63 (2009) 147-51. Published, 03/2009.